BIO vs TEM · rev $2.58B vs rev $1.27B
BIO (BIO) versus Tempus AI, Inc. Class A Common Stock (TEM) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Tempus AI, Inc. Class A Common Stock (TEM) is a health information services company listed on NASDAQ.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
Latest reported TEM revenue for 2025-12-31 was $1.27B. Net income was -$245.0M. Revenue was up 83.4% from 2024-12-31 to 2025-12-31. TEM currently screens at market cap $8.76B.
BIO currently screens at market cap $0. TEM currently screens at market cap $8.76B.
Not investment advice. Open the BIO and TEM stock pages for the full models.
Not investment advice.